Advagraf®
Sponsors
Astellas Pharma Inc, Hannover Medical School, Astellas Pharma Canada, Inc., Chiesi Farmaceutici S.p.A., Kim, Seoung-Hoon
Conditions
End Stage Renal DiseaseHealthyKidney TransplantKidney TransplantationLiver TransplantationLung TransplantationOrgan or Tissue Transplant; Complications
Phase 1
A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers
CompletedNCT01681134
Start: 2012-07-31End: 2012-10-31Updated: 2012-11-08
Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
WithdrawnNCT03978494
Start: 2019-09-02End: 2020-05-03Updated: 2019-09-17
Phase 3
Phase 4
A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection
CompletedNCT00717470
Start: 2008-05-14End: 2010-03-02Updated: 2024-11-01
Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation
CompletedNCT02161237
Start: 2014-06-26End: 2016-12-22Updated: 2024-10-31
Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
CompletedNCT02432833
Start: 2015-05-31End: 2017-01-24Updated: 2018-04-13
Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients
CompletedNCT02500212
Start: 2015-07-31End: 2016-06-30Updated: 2020-07-31
To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
CompletedNCT03423225
Start: 2016-03-22End: 2017-12-14Updated: 2018-02-06
To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
CompletedNCT04761731
Start: 2015-07-31End: 2017-12-14Updated: 2021-02-21